Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on September 7, 2017, reporting events occurring on September 3, 2017. The filing addresses the formalization of employment terms for the Company's interim Chief Executive Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On September 3, 2017, the Company entered into an Offer Letter with Anthony G. Quinn, the interim Chief Executive Officer. The key terms include:
- Base Salary: $480,000 annually.
- Annual Bonus: Eligible for up to 50% of base salary based on performance objectives set by the Board.
- Stock Option Grant: 150,000 shares of common stock.
- Exercise Price: $4.11 per share.
- Vesting Schedule: 100% of shares vest on July 18, 2018, contingent on continued service.
- Acceleration Clause: Full vesting accelerates upon the closing of a "Corporate Transaction."
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency noted is the acceleration of stock option vesting in the event of a Corporate Transaction.
Investor Verification Checklist
- Verify the distinction between the registrant (Aeglea BioTherapeutics, Inc.) and the company name mentioned in the request metadata (Spyre Therapeutics, Inc.).
- Confirm the total potential annual compensation value ($480,000 base + up to $240,000 bonus).
- Review the 2016 Equity Incentive Plan to understand the specific definition of a "Corporate Transaction" triggering option acceleration.
- Check subsequent filings to confirm if Dr. Quinn remained in service through the July 18, 2018 vesting date.